Your AI-Trained Oncology Knowledge Connection!

Optimizing Therapy for Patients with Acute and Chronic Graft-Versus-Host Disease (GvHD) : Episode 9

Video

August 4, 2023

Data-Driven Treatment Selection for Patients with Chronic GvHD

Author(s):

Michael R. Bishop, MD, University of Chicago,Hannah Choe, MD

Clinical pearls for community oncologists regarding treatment selection and sequencing in chronic GvHD patients.

EP: 1.Understanding Chronic and Acute Graft-Versus-Host Disease Presentation and Diagnosis

EP: 2.Improving Patient Outcomes: Prophylactic Options in Graft-Versus-Host Disease

EP: 3.Optimal First-Line Treatment Approaches for Acute GvHD

EP: 4.Treatment Options in Steroid-Refractory Acute GvHD

EP: 5.Enhancing Patient Care in Acute GvHD: Supportive Measures

EP: 6.Advancements and Promising Directions in Acute GvHD

EP: 7.Establishing Treatment Objectives for Chronic GvHD: First-Line Strategies

EP: 8.A Comprehensive Look at Initial Treatment Options for Chronic GvHD

Now Viewing

EP: 9.Data-Driven Treatment Selection for Patients with Chronic GvHD

EP: 10.Remote Patient Monitoring and Supportive Care Measures in Chronic GvHD

EP: 11.The Future of Chronic GvHD Treatment

EP: 12.Dr Rifkin on the Role of Belantamab Mafodotin in Relapsed/Refractory Multiple Myeloma

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All

Video

(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments

Apr 23rd 2025 - Apr 24th 2026

online-activity

Video

Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2

Apr 23rd 2025 - Apr 24th 2026

online-activity

Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Apr 18th 2025 - Apr 19th 2026

online-activity

Latest Conference Coverage

Oncology Experts Preview Top Abstracts From AUA 2025

Future of Bispecifics and CAR T in R/R MM

Choosing Between Bispecifics and CAR T: Real-World Implications in R/R MM

Overview of iMMagine-1 Trial: Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of R/R MM

View More Latest Conference Coverage

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Privacy

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

Data-Driven Treatment Selection for Patients with Chronic GvHD

EP: 1.Understanding Chronic and Acute Graft-Versus-Host Disease Presentation and Diagnosis

EP: 2.Improving Patient Outcomes: Prophylactic Options in Graft-Versus-Host Disease

EP: 3.Optimal First-Line Treatment Approaches for Acute GvHD

EP: 4.Treatment Options in Steroid-Refractory Acute GvHD

EP: 5.Enhancing Patient Care in Acute GvHD: Supportive Measures

EP: 6.Advancements and Promising Directions in Acute GvHD

EP: 7.Establishing Treatment Objectives for Chronic GvHD: First-Line Strategies

EP: 8.A Comprehensive Look at Initial Treatment Options for Chronic GvHD

EP: 9.Data-Driven Treatment Selection for Patients with Chronic GvHD

EP: 10.Remote Patient Monitoring and Supportive Care Measures in Chronic GvHD

EP: 11.The Future of Chronic GvHD Treatment

EP: 12.Dr Rifkin on the Role of Belantamab Mafodotin in Relapsed/Refractory Multiple Myeloma

Newsletter

Latest CME

Addressing Unmet Needs in HER2+ Metastatic BTC

Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota

(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments

Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2

Addressing Unmet Needs in HER2+ Metastatic BTC

Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota

(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments

Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2

Addressing Unmet Needs in HER2+ Metastatic BTC

Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota

Latest Conference Coverage